TheraRadar
Company Portfolios →

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

31 active trials across 6 therapeutic areas

31
Active Trials
16
Phase 1
12
Phase 2
6
Phase 3
6
Therapeutic Areas
Portfolio Concentration: 77% of active trials in Oncology

Oncology

24 active / 28 total
Breast Cancer
6 active 3 Ph3
6 total since 2015
Solid Tumor (Advanced)
4 active
5 total since 2015
Colorectal Cancer
3 active 1 Ph3
3 total since 2015
Multiple Myeloma
2 active
2 total since 2015
NSCLC
2 active
2 total since 2015
Cholangiocarcinoma
1 active
1 total since 2015
HER2+ Breast Cancer
1 active 1 Ph3
1 total since 2015
Hematologic Malignancies
1 active
1 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Lung Cancer (General)
1 active
1 total since 2015
CML
1 active
1 total since 2015
Sarcoma
0 active
2 total since 2015
Non-Hodgkin Lymphoma
0 active
1 total since 2015

Immunology

3 active / 7 total
Psoriasis
1 active
4 total since 2015
Psoriatic Arthritis
1 active
1 total since 2015
IBD
1 active
1 total since 2015
Ankylosing Spondylitis
0 active
1 total since 2015

Urology

2 active / 2 total
Erectile Dysfunction
2 active
2 total since 2015

Respiratory

1 active / 2 total
COPD
1 active
1 total since 2015
Allergic Rhinitis
0 active
1 total since 2015

Metabolic

1 active / 1 total
NASH/NAFLD
1 active
1 total since 2015

Rare Disease

1 active / 1 total
Hemophilia
1 active 1 Ph3
1 total since 2015

Click an indication to see competitive landscape (all sponsors in that indication).

Data: ClinicalTrials.gov (2015+)